Leukemia
Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.
Marianne Ayoub, Casilda Hitier, Léa Dehgane, Eliane Mallet, Mariana Tannoury, Ivan Nemazanyy, Damien Roos-Weil, Karim Maloum, Ingo Ringshausen, Elise Chapiro, Florence Nguyen-Khac, Delphine Garnier, Marie Lagouge, Leticia K Lerner, Santos A Susin
Published: 202610.1038/s41375-025-02846-6
No abstract available for this study.